[go: up one dir, main page]

PL359624A1 - Clear aqueous anaesthetic composition - Google Patents

Clear aqueous anaesthetic composition

Info

Publication number
PL359624A1
PL359624A1 PL00359624A PL35962400A PL359624A1 PL 359624 A1 PL359624 A1 PL 359624A1 PL 00359624 A PL00359624 A PL 00359624A PL 35962400 A PL35962400 A PL 35962400A PL 359624 A1 PL359624 A1 PL 359624A1
Authority
PL
Poland
Prior art keywords
clear aqueous
propofol
compositions
composition
hydroxypropyl
Prior art date
Application number
PL00359624A
Other languages
Polish (pl)
Inventor
Srikanth Pai
Sangeeta Rivankar
Shilpa Kocharekar
Original Assignee
Bharat Serums & Vaccines Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bharat Serums & Vaccines Ltd. filed Critical Bharat Serums & Vaccines Ltd.
Publication of PL359624A1 publication Critical patent/PL359624A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Anesthesiology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Sterile pharmaceutical stable autoclaved clear aqueous compositions of propofol (2,6-Diisopropyl phenol) suitable for parenteral administration are described. The compositions essentially consist of a complex of propofol with 2-hydroxypropyl-beta-cyclodextrin in a weight ratio of 1:30-1:60. This complex of propofol with 2-hydroxypropyl-beta-cyclodextrin produces a clear aqueous composition that is stable to autoclaving. The composition is effective as an anaesthetic agent. The process of making these synergistic compositions has been described.
PL00359624A 2000-06-21 2000-12-14 Clear aqueous anaesthetic composition PL359624A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN573MU2000 IN187686B (en) 2000-06-21 2000-06-21
PCT/IN2000/000124 WO2001097796A1 (en) 2000-06-21 2000-12-14 Clear aqueous anaesthetic composition

Publications (1)

Publication Number Publication Date
PL359624A1 true PL359624A1 (en) 2004-08-23

Family

ID=11097257

Family Applications (1)

Application Number Title Priority Date Filing Date
PL00359624A PL359624A1 (en) 2000-06-21 2000-12-14 Clear aqueous anaesthetic composition

Country Status (26)

Country Link
US (1) US7138387B2 (en)
EP (1) EP1299095B1 (en)
JP (1) JP4907833B2 (en)
KR (1) KR100810066B1 (en)
CN (1) CN1254237C (en)
AP (1) AP2002002674A0 (en)
AT (1) ATE267592T1 (en)
AU (2) AU3597201A (en)
BG (1) BG107463A (en)
BR (1) BR0017268A (en)
CA (1) CA2414064C (en)
DE (1) DE60011149T2 (en)
DK (1) DK1299095T3 (en)
EA (1) EA005589B1 (en)
ES (1) ES2222271T3 (en)
HU (1) HUP0301646A3 (en)
IL (1) IL153387A0 (en)
IN (1) IN187686B (en)
MX (1) MXPA02012611A (en)
NO (1) NO20025999D0 (en)
NZ (1) NZ523643A (en)
PL (1) PL359624A1 (en)
PT (1) PT1299095E (en)
WO (1) WO2001097796A1 (en)
YU (1) YU2703A (en)
ZA (1) ZA200300336B (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN188917B (en) * 2000-12-07 2002-11-23 Bharat Surums & Vaccines Ltd
US7034013B2 (en) 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
KR20100112632A (en) * 2001-12-28 2010-10-19 에이자이 아이엔씨. Pharmaceutical Aqueous Formulations of Water Soluble Propofol Prodrugs
CA2474710A1 (en) * 2002-02-01 2003-08-07 Shimoda Biotech (Pty) Ltd Freeze-dried pharmaceutically acceptable inclusion complexes of propofol and cyclodextrin
JP2005538191A (en) * 2002-07-29 2005-12-15 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド Aqueous 2,6-diisopropylphenol pharmaceutical composition
US7550155B2 (en) 2002-07-29 2009-06-23 Transform Pharmaceuticals Inc. Aqueous pharmaceutical compositions of 2,6-diisopropylphenol (propofol) and their uses
KR20200083657A (en) * 2002-12-09 2020-07-08 아브락시스 바이오사이언스, 엘엘씨 Compositions and methods of delivery of pharmacological agents
WO2005067905A1 (en) * 2004-01-14 2005-07-28 Otsuka Pharmaceutical Factory, Inc. Propofol-containing fat emulsion preparation
CA2580202A1 (en) * 2004-09-13 2006-03-23 Bharat Serums & Vaccines Ltd. Stable emulsion compositions for intravenous administration having antimicrobial preservative efficacy
CA2618799C (en) * 2005-08-12 2013-06-04 Bharat Serums & Vaccines Ltd. Aqueous anaesthetic compositions comprising propofol
WO2007128866A2 (en) * 2006-05-09 2007-11-15 Novobion Oy Novel chemical compositions
EP2712900A1 (en) * 2008-03-11 2014-04-02 3M Innovative Properties Company Phototools having a protective layer
WO2010148288A2 (en) * 2009-06-19 2010-12-23 Lyotropic Therapeutics, Inc. Pharmaceutical formulations with low aqueous levels of free unbound drug
JP5583210B2 (en) 2009-07-21 2014-09-03 スリーエム イノベイティブ プロパティズ カンパニー Curable composition, method for coating a phototool, and coated phototool
EP2478034A1 (en) 2009-09-16 2012-07-25 3M Innovative Properties Company Fluorinated coating and phototools made therewith
WO2011034847A1 (en) 2009-09-16 2011-03-24 3M Innovative Properties Company Fluorinated coating and phototools made therewith
US8268067B2 (en) * 2009-10-06 2012-09-18 3M Innovative Properties Company Perfluoropolyether coating composition for hard surfaces
EP2345427A1 (en) * 2010-01-14 2011-07-20 SapioTec GmbH Fluoran complex
EP2484350B1 (en) * 2011-02-04 2016-04-20 Roewer, Norbert, Univ.-Prof. Dr. med. Pharmaceutical preparation containing a complex of a salt of propofol and a cyclodextrin
KR101922752B1 (en) 2011-11-29 2018-11-27 주록스 피티와이 리미티드 Methods of preserving injectable pharmaceutical compositions comprising a cyclodextrin and a hydrophobic drug
AU2013273764B2 (en) * 2011-11-29 2016-05-05 Zoetis Services Llc Pharmaceutical compositions
CN103263404B (en) * 2012-04-28 2017-12-01 中国人民解放军军事医学科学院放射与辐射医学研究所 A kind of composite anaesthetic
HRP20220005T1 (en) 2012-08-21 2022-04-01 Sage Therapeutics, Inc. Allopregnanolone for treating refractory status epilepticus
US10646439B2 (en) * 2016-01-29 2020-05-12 Cuda Anesthetics, Llc Aqueous pharmaceutical formulation comprising propofol
FR3117337B1 (en) 2020-12-10 2023-04-28 Centre Hospitalier Univ De Lille Pharmaceutical composition containing propofol, a cyclodextrin or a cyclodextrin derivative and a pharmaceutically acceptable salt

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA962214B (en) * 1995-04-10 1996-10-07 Farmarc Nederland Bv Pharmaceutical composition

Also Published As

Publication number Publication date
ZA200300336B (en) 2004-04-08
CA2414064A1 (en) 2001-12-27
KR20030023875A (en) 2003-03-20
CN1454085A (en) 2003-11-05
DE60011149T2 (en) 2005-07-07
HUP0301646A2 (en) 2003-09-29
AU2001235972B2 (en) 2005-07-21
AU3597201A (en) 2002-01-02
WO2001097796A1 (en) 2001-12-27
YU2703A (en) 2006-03-03
NZ523643A (en) 2004-05-28
BG107463A (en) 2003-11-28
AP2002002674A0 (en) 2002-12-31
MXPA02012611A (en) 2004-07-30
NO20025999L (en) 2002-12-13
JP2003535893A (en) 2003-12-02
DK1299095T3 (en) 2004-10-11
ES2222271T3 (en) 2005-02-01
PT1299095E (en) 2004-10-29
CN1254237C (en) 2006-05-03
EP1299095A1 (en) 2003-04-09
HUP0301646A3 (en) 2005-06-28
EP1299095B1 (en) 2004-05-26
DE60011149D1 (en) 2004-07-01
JP4907833B2 (en) 2012-04-04
BR0017268A (en) 2003-05-27
EA200300047A1 (en) 2003-06-26
CA2414064C (en) 2013-01-08
US20040014718A1 (en) 2004-01-22
ATE267592T1 (en) 2004-06-15
US7138387B2 (en) 2006-11-21
KR100810066B1 (en) 2008-03-05
NO20025999D0 (en) 2002-12-13
IL153387A0 (en) 2003-07-06
IN187686B (en) 2002-06-08
EA005589B1 (en) 2005-04-28

Similar Documents

Publication Publication Date Title
PL359624A1 (en) Clear aqueous anaesthetic composition
CA2910494C (en) Insulin-oligomer conjugates, formulations and uses thereof
BR0111206A (en) Arylmethylamine derivatives for use as tryptase inhibitors
UY26635A1 (en) SYNERGIC METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
DK1157037T3 (en) G-CSF-conjugates
ATE409048T1 (en) PHARMACEUTICALLY ACTIVE OLIGOSACCHARIDE CONJUGATES
SE0001899D0 (en) New compounds
TWI256891B (en) 17alpha-alkyl-17beta-oxy-estratrienes and intermediate products for their production, use of the 17alpha-alkyl-17beta-oxy-estratrienes for the production of pharmaceutical agents as well as pharmaceutical preparations
SG146648A1 (en) Pharmaceutical compositions for treating premature ejaculation by pulmonary inhalation
MXPA05001061A (en) Aqueous 2,6-diisopropylphenol pharmaceutical compositions.
CA2289202A1 (en) Solid pharmaceutical formulations containing a physical mixture of sulfoalkyl ether cyclodextrin and a therapeutic agent
BR0008590A (en) Polymeric delivery agent, composition, unit dosage form, method for administering a biologically active agent to an animal requiring the agent, method for preparing a composition; it's composed
NZ597354A (en) Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
BR9813811A (en) "pharmaceutical compositions comprising micelles comprising lipophilic glucocorticosteroid and only a single surfactant"
HUT75513A (en) Taxane class derivative based pharmaceutical compositions and their preparation
SI1819227T1 (en) Pharmaceutical formulation of decitabine
BR0109672A (en) Use of zd6126 or a pharmaceutically acceptable salt thereof and one of: a plantin antitumor agent and a taxane, pharmaceutical composition, combination product, kit, and method for producing a vascularly damaging effect on a warm-blooded animal
WO2007056263A3 (en) Methods of treating cancer with high potency lipid-based platinum compound formulations administered intravenously
HK1064954A1 (en) Clear propofol compositions
AR043110A1 (en) LOW MOLECULAR HEPARINE SALT WITH USEFUL TRIETHANOLAMINE AS A THERAPEUTIC-ANTITROMBOTIC AGENT OF TOPICAL ADMINISTRATION, PROCEDURES TO PREPARE SALES, PROCESS FOR THE ELIMINATION OF HYPROSCOPICITY SALT IN PHAROSERIC ACIACIACEUTIC USE IN TOP THERAPY PAPER USE
ES2105923B1 (en) COMPOSITIONS FOR THE TREATMENT OF AN INFECTION AND DISEASE CAUSED BY THE HEPATITIS B (HBV) VIRUS.
BR0109617A (en) Pharmaceutical composition, oligosaccharide, process for preparing oligosaccharides, and use of oligosaccharides
AU6749401A (en) Use of aloe-emodin in the treatment of neuroectodermal tumors
HUP0303379A2 (en) Acid-sensitive compounds, use thereof and pharmaceutical compositions containing them
BR0212915A (en) Use of a specific dose of fondaparinux sodium for the treatment of acs